Aplagon is proud to announce a significant funding milestone with a successful raise of $7,000,000 that will accelerate our mission of addressing critical unmet needs in vascular medicine. Founded on pioneering research by Riitta Lassila and associates at the Wihuri Research Institute in Helsinki, our clinical-stage biopharmaceutical company has been at the forefront of developing first-in-class therapeutics for thromboinflammatory diseases. This recent infusion of capital reinforces our commitment to advancing innovative treatments that provide targeted, long-term relief for conditions that challenge current therapeutic options. The funding will be strategically deployed to advance our lead therapeutic, APAC—a heparin proteoglycan mimetic with dual antiplatelet and anticoagulant properties—and to propel its clinical development forward. By specifically targeting vascular injury sites, APAC offers a unique approach with localized action that minimizes systemic exposure, positioning it as a promising candidate against thromboinflammatory conditions. Our clinical pipeline is focused on addressing challenging conditions such as arteriovenous fistula (AVF) maturation failure in hemodialysis patients and chronic limb threatening ischemia (CLTI), where there remains an urgent need to mitigate risks of amputations and major cardiovascular events. The new capital will support critical clinical trials and further research initiatives, facilitating rapid translational progress from our esteemed research origins to tangible patient benefits. As we step into this exciting phase of growth, we remain deeply committed to our vision of transforming vascular medicine and improving patient outcomes worldwide through first-in-class therapeutic solutions.
Aplagon Secures $7M to Accelerate First-in-Class Thromboinflammatory Therapeutics Development
Get the full Aplagon company profile
Access contacts, investors, buying signals & more
Other recently funded companies
View all
Telepatia AI
Telepatia AI is a healthtech company on a mission to transform healthcare in Latin America and beyond. Born at Stanford and built by doctors for doctors, our platform introduces AI Healthcare Employees that work invisibly inside clinical workflows — transcribing consultations in real time, generating structured medical records, offering evidence-based decision support, and integrating seamlessly with any current health system — all without disrupting the physician’s flow. Already adopted by thousands of doctors and leading hospitals across the region, Telepatia has demonstrated measurable impact: reducing cognitive load, improving patient experience, and increasing adherence to clinical protocols. Our vision is bold: to turn scarcity into abundance by empowering healthcare professionals with scalable, trustworthy intelligence — and to pursue nothing less than the first Nobel Prize in Medicine for Latin America since 1984 with an AI Doctor.
$42.0M Series a
today
OneSoil
OneSoil transforms agricultural decisions from guesswork to data-driven precision. We help farmers and enterprises maximize profitability and sustainability through satellite intelligence and field-level insights. For Farmers & Agronomists: Our easy-to-use platform puts actionable data in your pocket. Scout fields efficiently with our mobile app, identify problem spots in real-time, and optimize input applications down to the hectare. For Enterprises: We deliver global agricultural intelligence at scale. Covering 59 countries with crop detection, yield forecasting, and supply chain monitoring - our data arrives 8 months ahead of official statistics, giving you the competitive edge that matters in commodity markets and strategic planning. The Same Technology, Two Markets Whether you're protecting your farm's bottom line or making billion-dollar decisions across global supply chains, OneSoil's satellite-derived insights, proprietary algorithms, and machine learning deliver precision agriculture that actually pays off. Quick to implement. Proven results. Built for real-world farming.
$1.2M Seed
today
Edvisor
Edvisor is the #1 Student Recruitment Software that helps international education companies streamline the way they sell education - whether they recruit students directly, through agencies or both. Supported by the biggest network of agencies, institutions and service providers, with more than 10K registered users across 42 countries and exclusive partnerships with the best associations and industry organizations.
$1.3M Pre-seed
today
Spoon Cereals
We find mornings just as hard as the next person, which is why we set out to make breakfast better for everyone...Better tasting, better for you and better for the planet. Our granolas are made with quality, good-for-you ingredients and baked in small batches, which means fresher granola and less waste.
$1.9M Seed
today
HyperLight
The information age relies on billions of devices converting signals between electricity and light waves. These integrated light circuits are the backbone of telecommunication infrastructures, data centers, sensors, and even secure quantum communications. Our devices set new benchmarks for performance, including extraordinary speed and efficiency, that will force industries to rethink and reimagine their current standards.
$80.0M Series c
today